Timothy J. Ley - Shoreview MN Graig L. Kveen - Maple Grove MN Burns P. Doran - Albertville MN
Assignee:
SciMed Life Systems, Inc. - Maple Grove MN
International Classification:
A61F 206
US Classification:
623 115
Abstract:
A generally cylindrical, radially expandable stent may be composed of a plurality of interconnected multibonate cell structures. The cells have three or more enlarged end portions radiating from a common center within the cell. The cells may be of tribonate or higher order multibonate configuration. Stents composed up of a series of generally multibonate cell elements are also disclosed.
Timothy J. Ley - Shoreview MN Graig L. Kveen - Maple Grove MN Timothy G. J. Ehr - Elk River MN Brian J. Brown - Hanover MN David L. Friesen - Brooklyn Park MN
Assignee:
Scimed Life Systems, Inc. - Maple Grove MN
International Classification:
A61F 206
US Classification:
623 115
Abstract:
Improved stent configurations exhibiting limited recoil, resistance to compression and improved longitudinal flexibility.
Burns P. Doran - Albertville MN Graig L. Kveen - Maple Grove MN Timothy J. Ley - Shoreview MN
Assignee:
SciMed Life Systems, Inc. - Maple Grove MN
International Classification:
A61F 206
US Classification:
623 115
Abstract:
A stent comprises at least one band of interconnected cells selected from the group consisting of S-shaped cells and mirror image S-shaped cells. Each cell has a top end and a bottom end. The top end of each cell is attached to the bottom end of an adjacent cell in the band. Adjacent bands may abut one another or may be joined by connecting members.
Burns P. Doran - Albertville MN, US Jason Todd Lenz - Maplewood MN, US Graig L. Kveen - Maple Grove MN, US Timothy Samuel Girton - Minneapolis MN, US James F. Hemerick - Champlin MN, US Timothy J. Ley - Shoreview MN, US
Assignee:
SciMed Life Systems, Inc. - Maple Grove MN
International Classification:
A61F029/00
US Classification:
623 115
Abstract:
In one embodiment of the invention, a stent may be provided comprising a first undulating band comprising a series of alternating first peaks and first troughs and a second undulating band comprising a series of alternating second peaks and second troughs. The first undulating band has a first wavelength and a first amplitude and the second undulating band has a second wavelength and a second amplitude where the second amplitude is different from the first amplitude and the second wavelength is different from the first wavelength. A plurality of longitudinally oriented first connectors extend between the first peaks and second peaks.
Timothy Girton - Edina MN, US Timothy Ley - Shoreview MN, US
Assignee:
Boston Scientific Scimed, Inc. - Maple Grove MN
International Classification:
A61F 2/06
US Classification:
623 115
Abstract:
An intraluminal medical device having a flowpath therethrough, the device including a plurality of substantially cylindrical serpentine shaped segments which define a generally tubular body, each serpentine segment having a plurality of struts interconnected by alternating end portions, segments which are adjacent one another connected one to the other. The medical device has a pre-crimped diameter and crimped diameter and is constructed and arranged such that as the cylindrical shaped segments are crimped from the pre-crimped diameter to the crimped diameter at least some of the end portions project into the flowpath.
Timothy J. Ley - Shoreview MN, US Brian J. Brown - Hanover MN, US
Assignee:
Boston Scientific Scimed, Inc. - Maple Grove MN
International Classification:
A61F 2/06
US Classification:
623 115, 606196
Abstract:
A stent may be formed having a reduced state and an expanded state. The stent having a longitudinal axis therethrough. The stent comprises at least one serpentine segment having a proximal end and a distal end. The serpentine segment comprises a plurality of peaks and troughs, wherein the peaks are disposed at the distal end of the segment and the troughs are disposed at the proximal end of the segment. The peaks include first peaks and second peaks arranged in a regular alternating pattern about the longitudinal axis. In the reduced state the first peaks disposed at a first distance from the longitudinal axis of the stent and the second peaks disposed at a second distance from the longitudinal axis of the stent. The second distance is less than the first distance. The first peaks defining a substantially cylindrical outer surface of the segment.
Dr. Ley graduated from the Washington University School of Medicine in 1978. He works in Saint Louis, MO and specializes in Hematology/Oncology. Dr. Ley is affiliated with Barnes Jewish Hospital.
Timothy J Ley is an American hematologist, oncologist and cancer biologist. He is the Lewis T. and Rosalind B. Apple Professor of Oncology in the Department of
Timothy Ley 1995 graduate of Butler High School in Butler, PA is on Memory Lane. Get caught up with Timothy and other high school alumni from Butler High School.
So one day last July, Dr. Timothy Ley, associate director of the universitys genome institute,summoned his team. Why not throw everything we have at seeing if we can find a rogue gene spurringWartmans cancer, adult acute lymphoblastic leukemia, he asked? Its now or never, he recalledtelling
"Whole-genome sequencing is the most powerful diagnostic tool we've ever had to define all the mutations in the genome of a cancer patient," says co-author Timothy Ley, MD, the Lewis T. and Rosalind B. Apple Professor of Oncology at Washington University. "We no longer have to rely on techniques whe
Washington University oncology professor Timothy Ley, MD, calls whole-genome sequencing the most powerful diagnostic tool ever for understanding specific mutations that influence cancer susceptibility.
Date: Apr 20, 2011
Category: Health
Source: Google
Whole-Genome Testing Offers Promise For Cancer Diagnosis
According to oncology professor Timothy Ley of Washington University, whole-genome sequencing could be the most powerful diagnostic tool ever for finding the mutations that lead to certain cancers.
Sifting through the genetic "noise" to find the handful of mutations in each tumor that drive cancer development is challenging, researchers say. Timothy Ley and colleagues at Washington University School of Medicine in St. Louis thought the work could be simplified if they looked for mutations in m